Who Benefits Most from PTH Therapy? Patient Selection, Goals of Care, and Renal Protection

Determining which patients with chronic hypoparathyroidism should receive PTH replacement is increasingly guided by expert consensus. In this segment of the HCPLive Special Report, Sara Lubitz, MD, highlights recommendations from the 2022 Second International Workshop on the Evaluation and Management of Hypoparathyroidism.

These guidelines consider patients inadequately controlled on conventional therapy—those with symptomatic hypocalcemia, hyperphosphatemia, renal insufficiency, hypercalciuria, or poor well-being—as candidates who may benefit from therapies such as palopegteriparatide. Additional triggers include a requirement for high doses of oral calcium (>2 g/day) or active vitamin D (>2 mcg/day), intolerance or nonadherence to multiple daily pills, and malabsorption syndromes.

Lubitz reviews 6 major goals of care for chronic hypoparathyroidism. First, clinicians should avoid the signs and symptoms of hypocalcemia, including overt manifestations such as tetany and seizures as well as more subtle complaints like fatigue and cognitive dysfunction. Second, serum calcium should be maintained within a narrow therapeutic range; historically, guidelines recommended aiming for the lower end of normal or slightly below to avoid toxicity on conventional therapy, whereas PTH replacement can often normalize calcium without driving hypercalciuria.

Additional objectives include maintaining the calcium-phosphate product below 55 to reduce extraskeletal calcifications, avoiding hypercalciuria, and preventing hypercalcemia. Lubitz argues that improvement in quality of life should be explicitly recognized as another primary treatment goal, even though it is less easily quantified in busy practice.

Beyond symptom control and serum targets, Lubitz emphasizes the potential of PTH therapy to mitigate renal complications and reduce treatment burden. She notes that in the PATHWAY trial, patients treated with palopegteriparatide experienced a sustained, clinically meaningful rise in estimated glomerular filtration rate and a durable decline in 24-hour urinary calcium to normal ranges.

Pill burden was also markedly reduced: patients who began with an average of 6.7 “hypopara pills” per day (calcium and related agents) decreased to approximately 0.5 pills per day over 26 weeks. For many individuals, this represents a reduction of six or more tablets daily, which can have a substantial impact on adherence, quality of life, and overall treatment satisfaction.